12 completed, 1 withdrawn. 12 Phase 1, 4 Phase 2.
By phase and status
Follow XL147: new trials by email Literature Review of XL147 trials Research Report on XL147
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study of the Safety and Pharmacokinetics of SAR245408 Tablets in Patients With Solid Tumors or Lymphoma
SAR245408 - Neoplasm Malignant | Phase 1 | Completed | Sanofi | 18 | 2013-10-01 | 2016-04-22 |
Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen
SAR245408, SAR245409 - Neoplasm Malignant | Phase 1 / Phase 2 | Completed | Sanofi | 61 | 2012-07-20 | 2022-04-19 |
A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers
MM-121 (SAR256212), SAR245408 - Solid Tumor Cancers | Phase 1 | Completed | Sanofi | 26 | 2011-11-01 | 2014-06-13 |
Safety and Pharmacokinetics of SAR245408 Daily Oral in Patients With Solid Tumors
SAR245408 - Neoplasm Malignant | Phase 1 | Completed | Sanofi | 10 | 2011-08-01 | 2014-12-03 |
Oral SAR245408 (XL147) and Oral MSC1936369B in Patients With Locally Advanced or Metastatic Solid Tumors
SAR245408 (XL147), MSC1936369B - Solid Tumors | Phase 1 | Completed | Sanofi | 18 | 2011-05-01 | 2016-04-01 |
Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection
XL765 (SAR245409), XL147 (SAR245408) - Glioblastoma, Astrocytoma, Grade IV | Phase 1 | Completed | Sanofi | 40 | 2011-01-01 | 2012-07-27 |
Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer
XL147 (SAR245408), XL765 (SAR245409), letrozole (Femara) - Breast Cancer | Phase 1 / Phase 2 | Completed | Sanofi | 72 | 2010-06-01 | 2016-06-03 |
Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen
XL147 (SAR245408), trastuzumab, paclitaxel - Breast Cancer, Breast Neoplasms | Phase 1 / Phase 2 | Completed | Sanofi | 42 | 2010-02-01 | 2016-06-03 |
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
XL147 (SAR245408) - Endometrial Cancer, Endometrial Neoplasms | Phase 2 | Completed | Sanofi | 67 | 2010-01-01 | 2016-06-03 |
Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors
XL147 (SAR245408),, paclitaxel, carboplatin - Cancer, Non-Small Cell Lung Cancer | Phase 1 | Completed | Sanofi | 52 | 2008-09-01 | 2013-04-10 |
Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors
XL647, XL147 - Cancer, Non-small-cell Lung Cancer | Phase 1 | Withdrawn | Exelixis | | 2008-06-01 | 2015-08-20 |
Safety Study of XL147 (SAR245408) in Combination With Erlotinib in Adults With Solid Tumors
XL147 (SAR245408), Erlotinib - Cancer, Non-small Cell Lung Cancer | Phase 1 | Completed | Sanofi | 35 | 2008-05-01 | 2012-03-23 |
Study of the Safety and Pharmacokinetics of XL147 (SAR245408) in Adults With Solid Tumors or Lymphoma
XL147 (SAR245408) - Cancer, Lymphoma | Phase 1 | Completed | Sanofi | 118 | 2007-06-01 | 2013-02-01 |
Conditions studied
Neoplasms (7) · Breast Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (3) · Endometrial Neoplasms (2) · Glioblastoma (1) · Lymphoma (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1)
Sponsors
Sanofi (12) · Exelixis (1)
Countries
United States (11) · Spain (4) · Belgium (3) · France (2) · Japan (1)
Results publications
PMID 25669662, PMID 28275119, PMID 29593099